Patents by Inventor Mircea Ivan
Mircea Ivan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220291216Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: November 20, 2020Publication date: September 15, 2022Applicant: Dana Farber Cancer Insitute, Inc.Inventors: William G. KAELIN, Mircea IVAN
-
Publication number: 20200209239Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: June 6, 2019Publication date: July 2, 2020Applicant: Dana Farber Cancer Institute, Inc.Inventors: William G. KAELIN, JR., Mircea Ivan
-
Patent number: 10365278Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: GrantFiled: May 12, 2017Date of Patent: July 30, 2019Assignee: Dana Farber Cancer InstituteInventors: William G. Kaelin, Jr., Mircea Ivan
-
Publication number: 20170350891Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: May 12, 2017Publication date: December 7, 2017Applicant: Dana Farber Cancer Institute, Inc.Inventors: William G. KAELIN, JR., Mircea Ivan
-
Patent number: 9766240Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: GrantFiled: July 10, 2014Date of Patent: September 19, 2017Assignee: Dana Farber Cancer InstituteInventors: William G. Kaelin, Jr., Mircea Ivan
-
Publication number: 20150010576Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: July 10, 2014Publication date: January 8, 2015Applicant: Dana Farber Cancer Institute, Inc.Inventors: William G. Kaelin, JR., Mircea Ivan
-
Patent number: 8809011Abstract: The present invention provides methods of identifying compounds that decrease proline hydroxylation of the alpha subunit of hypoxia inducible factor (HIF?).Type: GrantFiled: April 4, 2011Date of Patent: August 19, 2014Assignee: Dana Farber Cancer InstituteInventors: William G. Kaelin, Jr., Mircea Ivan
-
Publication number: 20130115221Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: April 4, 2011Publication date: May 9, 2013Applicant: Dana Farber Cancer Institute, Inc.Inventors: William G. Kaelin, JR., Mircea Ivan
-
Patent number: 7985563Abstract: The present invention provides methods of identifying compounds that decrease proline hydroxylation of the alpha subunit of hypoxia inducible factor (HIF?).Type: GrantFiled: July 17, 2007Date of Patent: July 26, 2011Assignee: Dana Farber Cancer Institute, Inc.Inventors: William G. Kaelin, Jr., Mircea Ivan
-
Publication number: 20100233735Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: August 13, 2008Publication date: September 16, 2010Applicant: Dana Farber Cancer InstituteInventors: William G. Kaelin, JR., Mircea Ivan
-
Publication number: 20090029400Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: July 17, 2007Publication date: January 29, 2009Applicant: Dana Farber Cancer InstituteInventors: William G. Kaelin, JR., Mircea Ivan
-
Patent number: 7361463Abstract: The present invention provides hypoxia inducible factor alpha muteins, DNA sequences encoding these hypoxia inducible factor alpha muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an hypoxia inducible factor alpha muteins, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing hypoxia inducible factor alpha muteins and methods of using those compositions to treat hypoxia and ischemic related tissue damage.Type: GrantFiled: May 26, 2004Date of Patent: April 22, 2008Assignee: Dana Farber Cancer Institute, Inc.Inventors: William G. Kaelin, Jr., Mircea Ivan
-
Publication number: 20050186650Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: December 30, 2004Publication date: August 25, 2005Inventors: William Kaelin, Mircea Ivan
-
Patent number: 6855510Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. Tie ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: GrantFiled: March 19, 2002Date of Patent: February 15, 2005Assignee: Dana Farber Cancer Institute, Inc.Inventors: William G. Kaelin, Jr., Mircea Ivan
-
Patent number: 6849718Abstract: The present invention provides hypoxia inducible factor alpha muteins, DNA sequences encoding these hypoxia inducible factor alpha muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an hypoxia inducible factor alpha muteins, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing hypoxia inducible factor alpha muteins and methods of using those compositions to treat hypoxia and ischemic related tissue damage.Type: GrantFiled: March 19, 2002Date of Patent: February 1, 2005Assignee: Dana Farber Cancer Institute, Inc.Inventors: William G. Kaelin, Jr., Mircea Ivan
-
Publication number: 20040248233Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: June 2, 2004Publication date: December 9, 2004Inventors: William G. Kaelin, Mircea Ivan
-
Publication number: 20040219635Abstract: The present invention provides hypoxia inducible factor alpha muteins, DNA sequences encoding these hypoxia inducible factor alpha muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an hypoxia inducible factor alpha muteins, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing hypoxia inducible factor alpha muteins and methods of using those compositions to treat hypoxia and ischemic related tissue damage.Type: ApplicationFiled: May 26, 2004Publication date: November 4, 2004Inventors: William G. Kaelin, Mircea Ivan
-
Publication number: 20030045686Abstract: The present invention provides hypoxia inducible factor alpha muteins, DNA sequences encoding these hypoxia inducible factor alpha muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an hypoxia inducible factor alpha muteins, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing hypoxia inducible factor alpha muteins and methods of using those compositions to treat hypoxia and ischemic related tissue damage.Type: ApplicationFiled: March 19, 2002Publication date: March 6, 2003Inventors: William G. Kaelin, Mircea Ivan
-
Publication number: 20020192737Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. Tie ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: March 19, 2002Publication date: December 19, 2002Inventors: William G. Kaelin, Mircea Ivan